Skip to content
Subscriber Only

Biogen Boosts 2013 Forecast as Tecfidera Tops Estimates

Biogen Idec Inc., the maker of multiple sclerosis drugs Avonex, Tysabri and Tecfidera, boosted its 2013 forecast after Tecfidera sales topped analysts’ third-quarter estimates.

Revenue this year will grow by 23 percent to 25 percent, with adjusted earnings of $8.65 to $8.85 a share, the Weston, Massachusetts-based drugmaker said today in a statement. The company previously had projected revenue gaining 22 percent to 23 percent and adjusted earnings of $8.25 to $8.50 a share.